The Journey of AOD 9604: From Clinical Trials to Cosmetic Triumphs The FDA has repeatedly flagged AOD 9604 as a compound of concern. It was placed on the Category 2 list in 2023 bulk drug substances in compounding that may present significant AOD9604 PEPTIDE LIQUID SPRAY 15ML BOTTLE UMBRELLA Labs How Does AOD 9604 Compare to Ozempic and GLP 1s? The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York